Huons Global (A084110) Stock Overview
Manufactures and sells pharmaceutical products for human health in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
A084110 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Huons Global Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩48,750.00 |
| 52 Week High | ₩65,900.00 |
| 52 Week Low | ₩29,300.00 |
| Beta | 1.04 |
| 1 Month Change | -15.36% |
| 3 Month Change | 10.54% |
| 1 Year Change | 61.42% |
| 3 Year Change | 161.39% |
| 5 Year Change | 73.94% |
| Change since IPO | 120.59% |
Recent News & Updates
Does Huons Global (KOSDAQ:084110) Have A Healthy Balance Sheet?
Oct 16
Huons Global Co., Ltd.'s (KOSDAQ:084110) 30% Share Price Surge Not Quite Adding Up
Oct 16Recent updates
Does Huons Global (KOSDAQ:084110) Have A Healthy Balance Sheet?
Oct 16Huons Global Co., Ltd.'s (KOSDAQ:084110) 30% Share Price Surge Not Quite Adding Up
Oct 16Investors Appear Satisfied With Huons Global Co., Ltd.'s (KOSDAQ:084110) Prospects As Shares Rocket 27%
May 02Huons Global's (KOSDAQ:084110) Soft Earnings Are Actually Better Than They Appear
Mar 28Huons Global Co., Ltd.'s (KOSDAQ:084110) Shares Climb 33% But Its Business Is Yet to Catch Up
Mar 17These 4 Measures Indicate That Huons Global (KOSDAQ:084110) Is Using Debt Extensively
Mar 11Revenues Not Telling The Story For Huons Global Co., Ltd. (KOSDAQ:084110) After Shares Rise 26%
Dec 14Huons Global (KOSDAQ:084110) Takes On Some Risk With Its Use Of Debt
Dec 04Subdued Growth No Barrier To Huons Global Co., Ltd. (KOSDAQ:084110) With Shares Advancing 26%
Sep 24Is Huons Global Co., Ltd. (KOSDAQ:084110) An Attractive Dividend Stock?
May 06Huons Global's (KOSDAQ:084110) Earnings Are Weaker Than They Seem
Mar 18Do Huons Global's (KOSDAQ:084110) Earnings Warrant Your Attention?
Mar 12How Much Of Huons Global Co., Ltd. (KOSDAQ:084110) Do Insiders Own?
Feb 22We Think Huons Global (KOSDAQ:084110) Can Manage Its Debt With Ease
Feb 04
Huons Global Co., Ltd. (KOSDAQ:084110) Pays A ₩400 Dividend In Just Three Days
Dec 24Huons Global Co., Ltd.'s (KOSDAQ:084110) Stock Has Fared Decently: Is the Market Following Strong Financials?
Dec 22Here's What You Should Know About Huons Global Co., Ltd.'s (KOSDAQ:084110) 1.3% Dividend Yield
Nov 29Shareholder Returns
| A084110 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -17.1% | -1.9% | -3.9% |
| 1Y | 61.4% | 29.1% | 51.2% |
Return vs Industry: A084110 exceeded the KR Pharmaceuticals industry which returned 29.1% over the past year.
Return vs Market: A084110 exceeded the KR Market which returned 51.2% over the past year.
Price Volatility
| A084110 volatility | |
|---|---|
| A084110 Average Weekly Movement | 11.0% |
| Pharmaceuticals Industry Average Movement | 4.3% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.0% |
| 10% least volatile stocks in KR Market | 2.5% |
Stable Share Price: A084110's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A084110's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1965 | 118 | Sooyoung Song | huonsglobal.com |
Huons Global Co., Ltd. manufactures and sells pharmaceutical products for human health in South Korea and internationally. The company offers oral solid form products in the areas of circulatory system, metabolic, anti-pyretic analgesic anti-inflammatory, musculoskeletal system, digestive system, antihistamine, respiratory system, antibiotic, well-being, urogenital system, other chemotherapeutic, and others; and injections in the areas of anesthetic, antipyretic, analgesic, anti-inflammatory, skeletal muscle relaxant, antispasmodic, antihistamine, adrenocortical hormone, enzyme, mineral, solvent, calcium, hemostatic, antidote, antibiotic, metabolic, hyaluronic acid, well-being, anticoagulant, and others, as well as circulatory, respiratory, and other tissue cell systems. It also provides medical devices, eye drop products, and bio products.
Huons Global Co., Ltd. Fundamentals Summary
| A084110 fundamental statistics | |
|---|---|
| Market cap | ₩594.90b |
| Earnings (TTM) | ₩16.24b |
| Revenue (TTM) | ₩813.69b |
Is A084110 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A084110 income statement (TTM) | |
|---|---|
| Revenue | ₩813.69b |
| Cost of Revenue | ₩405.84b |
| Gross Profit | ₩407.85b |
| Other Expenses | ₩391.61b |
| Earnings | ₩16.24b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.33k |
| Gross Margin | 50.12% |
| Net Profit Margin | 2.00% |
| Debt/Equity Ratio | 26.0% |
How did A084110 perform over the long term?
See historical performance and comparisonDividends
Does A084110 pay a reliable dividends?
See A084110 dividend history and benchmarks| Huons Global dividend dates | |
|---|---|
| Ex Dividend Date | Nov 24 2025 |
| Dividend Pay Date | Dec 12 2025 |
| Days until Ex dividend | 1 day |
| Days until Dividend pay date | 17 days |
Does A084110 pay a reliable dividends?
See A084110 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/24 23:20 |
| End of Day Share Price | 2025/11/24 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Huons Global Co., Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyoseob Shin | Bookook Securities Co. Ltd |
| Eunyoung Jung | Korea Investment & Securities Co., Ltd. |
| Seung-Ho Lee | NH Investment & Securities Co., Ltd. |